Zacks Research Comments on Veeva Systems Inc.'s Q3 2025 Earnings (NYSE:VEEV)

Veeva Systems Inc. (NYSE:VEEV - Free Report) - Equities researchers at Zacks Research increased their Q3 2025 earnings per share estimates for shares of Veeva Systems in a research note issued to investors on Wednesday, September 18th. Zacks Research analyst R. Department now forecasts that the technology company will post earnings per share of $1.05 for the quarter, up from their prior estimate of $1.02. The consensus estimate for Veeva Systems' current full-year earnings is $4.20 per share. Zacks Research also issued estimates for Veeva Systems' Q1 2026 earnings at $1.06 EPS and Q4 2026 earnings at $1.19 EPS.

Several other research analysts have also issued reports on the company. Needham & Company LLC reaffirmed a "buy" rating and set a $260.00 target price on shares of Veeva Systems in a research report on Thursday, August 29th. Raymond James raised their target price on Veeva Systems from $230.00 to $235.00 and gave the stock an "outperform" rating in a research report on Thursday, August 29th. Citigroup raised their target price on Veeva Systems from $256.00 to $273.00 and gave the stock a "buy" rating in a research report on Tuesday, August 27th. Evercore ISI lowered their target price on Veeva Systems from $230.00 to $200.00 and set an "in-line" rating for the company in a research report on Friday, May 31st. Finally, Canaccord Genuity Group lowered their target price on Veeva Systems from $220.00 to $210.00 and set a "hold" rating for the company in a research report on Friday, May 31st. One research analyst has rated the stock with a sell rating, seven have issued a hold rating and sixteen have assigned a buy rating to the company. According to data from MarketBeat.com, Veeva Systems has a consensus rating of "Moderate Buy" and an average price target of $229.96.

Veeva Systems Price Performance

Shares of NYSE VEEV traded up $0.49 during mid-day trading on Friday, hitting $214.88. 1,336,254 shares of the stock traded hands, compared to its average volume of 973,861. Veeva Systems has a twelve month low of $162.72 and a twelve month high of $236.90. The company has a market cap of $34.80 billion, a PE ratio of 63.25, a price-to-earnings-growth ratio of 2.12 and a beta of 0.81. The firm has a 50 day simple moving average of $198.72 and a two-hundred day simple moving average of $201.80.

Insider Activity

In other news, SVP Jonathan Faddis sold 2,353 shares of the company's stock in a transaction that occurred on Wednesday, August 21st. The stock was sold at an average price of $200.00, for a total value of $470,600.00. Following the completion of the transaction, the senior vice president now directly owns 9,035 shares of the company's stock, valued at $1,807,000. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. 10.50% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Veeva Systems

Institutional investors and hedge funds have recently bought and sold shares of the company. Advisors Asset Management Inc. bought a new position in Veeva Systems during the first quarter valued at $28,000. DSM Capital Partners LLC purchased a new stake in shares of Veeva Systems during the fourth quarter worth $29,000. Vermillion & White Wealth Management Group LLC purchased a new stake in shares of Veeva Systems during the fourth quarter worth $32,000. Blue Trust Inc. lifted its position in shares of Veeva Systems by 3,460.0% during the second quarter. Blue Trust Inc. now owns 178 shares of the technology company's stock worth $33,000 after acquiring an additional 173 shares in the last quarter. Finally, First Financial Corp IN purchased a new stake in shares of Veeva Systems during the first quarter worth $35,000. 88.20% of the stock is owned by institutional investors.

About Veeva Systems

Veeva Systems Inc provides cloud-based software for the life sciences industry. It offers Veeva Commercial Cloud, a suite of software and analytics solutions, such as Veeva customer relationship management (CRM) that enable customer-facing employees at pharmaceutical and biotechnology companies; Veeva Vault PromoMats, an end-to-end content and digital asset management solution; Veeva Vault Medical that provides source of medical content across multiple channels and geographies; Veeva Crossix, an analytics platform for pharmaceutical brands; Veeva OpenData, a customer reference data solution; Veeva Link, a data application that allows link to generate real-time intelligence; and Veeva Compass includes de-identified and longitudinal patient data for the United States.